Cardax Pharma offers small molecule therapies for unmet medical needs such as hepatitis, arthritis, cardiovascular diseases, and more.
Cardax Pharmaceuticals develops proprietary small molecule therapies for large unmet medical needs where oxidative stress and inflammation play important causative roles—including dyslipidemia, metabolic disease, arthritis, cardiovascular disease, hepatitis, macular degeneration, and many others.Most anti-inflammatory drugs have significant safety and side effect issues that limit their utility. In contrast, the company’s proprietary, synthetic, natural compound derivatives represent a novel treatment approach that offers robust efficacy combined with exceptional safety, oral bioavailability, and tissue selectivity.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Mar 31, 2004 | Series Unknown | — | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Advantage Capital | — | Series Unknown |